Johnson & Johnson to Acquire Firefly Bio for $1 Billion, Boosting KRAS Tumor Pipeline
JNJ•Johnson & Johnson agreed to acquire Firefly Bio for $1 billion, expanding its oncology pipeline with the Firelink platform designed to target KRAS‐driven tumors. The deal is set to close by end-2026 pending regulatory approvals and complements J&J’s Q1 revenue growth of 10% to $24.1 billion and raised full-year outlook of $100.3–101.3 billion.
1. Acquisition Details
Johnson & Johnson has agreed to purchase Firefly Bio for $1 billion in cash, marking its latest move to strengthen its oncology offerings.
2. Firelink Platform Potential
Firefly's Firelink platform uses antibody-based delivery of protein-degrading drugs to selectively target tumors driven by KRAS mutations, addressing cancers that have resisted conventional therapies.
3. Integration Timeline and Approvals
The transaction is expected to close by the end of 2026, subject to standard regulatory approvals and other closing conditions.
4. Financial Impact and Outlook
The acquisition complements J&J's Innovative Medicine segment, which posted 10% first-quarter revenue growth to $24.1 billion and led the company to raise its full-year 2026 sales outlook to $100.3–101.3 billion.
